The potential global impact and cost-effectiveness of next-generation influenza vaccines: a modelling analysis
Authors:
- Lucy GoodfellowLGLucy Goodfellow
- Simon R ProcterSPSimon R Procter
- Mihaly KoltaiMKMihaly Koltai
- Naomi R WaterlowNWNaomi R Waterlow
- Johnny A N FilipeJFJohnny A N Filipe
- Carlos K H WongCWCarlos K H Wong
- Edwin van LeeuwenELEdwin van Leeuwen
- Next-Generation Influenza Vaccine Impact Modelling ContributorsNCNext-Generation Influenza Vaccine Impact Modelling Contributors
- Rosalind M EggoRERosalind M Eggo
- Mark JitMJMark Jit
Preprint
Abstract
Background Next-generation influenza vaccines (NGIVs) are in development and have the potential to achieve greater reductions in influenza burden, with resulting widespread health and economic benefits. Understanding the prices at which their market can be sustained and which vaccination strategies may maximise impact and cost-effectiveness, particularly in low- and middle-income countries, can provide a valuable tool for vaccine development and investment decision-making at a national and global level. To address this evidence gap, we projected the health and economic impact of NGIVs in 186 countries and territories. Methods and Findings We inferred current influenza transmission parameters from World Health Organization (WHO) FluNet data in regions defined by their transmission dynamics, and projected thirty years of influenza epidemics, accounting for demographic changes. Vaccines considered included current seasonal vaccines, vaccines with increased efficacy, duration, and breadth of protection, and universal vaccines, defined in line with the WHO Preferred Product Characteristics. We estimated cost-effectiveness of different vaccination scenarios using novel estimates of key health outcomes and costs. NGIVs have the potential to substantially reduce influenza burden: compared to no vaccination, vaccinating 50% of children aged under 18 annually prevented 1.3 (95% uncertainty range (UR): 1.2-1.5) billion infections using current vaccines, 2.6 (95% UR: 2.4-2.9) billion infections using vaccines with improved efficacy or breadth, and 3.0 (95% UR: 2.7-3.3) billion infections using universal vaccines. In many countries, NGIVs were cost-effective at higher prices than typically paid for existing seasonal vaccines. However, cross-subsidy may be necessary for improved vaccines to be cost-effective in lower income countries. This study is limited by the availability of accurate data on influenza incidence and influenza-associated health outcomes and costs. Furthermore, the model involves simplifying assumptions around vaccination coverage and administration, and does not account for societal costs or budget impact of NGIVs. How NGIVs will compare to the vaccine types considered in this model when developed is unknown. We conducted sensitivity analyses to investigate key model parameters. Conclusions This study highlights the considerable potential health and economic benefits of NGIVs, but also the variation in cost-effectiveness between high-income and low- and middle-income countries. This work provides a framework for long-term global cost-effectiveness evaluations, and contributes to a full value of influenza vaccines assessment to inform recommendations by WHO, providing a pathway to developing NGIVs and rolling them out globally.Keywords
This publication has 19 references indexed in Scilit:
- The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysisVaccine, 2023
- Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expendituresThe Lancet Global Health, 2023
- The global region-specific epidemiologic characteristics of influenza: World Health Organization FluNet data from 1996 to 2021International Journal of Infectious Diseases, 2023
- Severity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013–19: a surveillance-based cohort studyThe Lancet Infectious Diseases, 2022
- Influenza vaccines: Past, present, and futureReviews in Medical Virology, 2021
- Producing Standardized Country-Level Immunization Delivery Unit Cost EstimatesPharmacoEconomics, 2020
- Influenza Vaccine Effectiveness: Defining the H3N2 ProblemClinical Infectious Diseases, 2019
- Estimates of global seasonal influenza-associated respiratory mortality: a modelling studyThe Lancet, 2018
- Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control StudiesThe Journal of Infectious Diseases, 2017
- Influenza Vaccination Modifies Disease Severity Among Community-dwelling Adults Hospitalized With InfluenzaClinical Infectious Diseases, 2017